Posted inGastroenterology news Oncology
Dual Checkpoint Inhibition: Tiragolumab and Atezolizumab Set New Survival Benchmarks in Advanced Esophageal Squamous Cell Carcinoma
The Phase 3 SKYSCRAPER-08 trial demonstrates that adding the anti-TIGIT tiragolumab and anti-PD-L1 atezolizumab to chemotherapy significantly extends overall survival and progression-free survival in patients with treatment-naive, unresectable esophageal squamous cell carcinoma.
